Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502929 · ClinicalTrials.gov registry record · NA
Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT02502929: Completed NA study, sponsored by UConn Health.
NCT02502929 is a NA study that has completed, run by UConn Health. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502929, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
The primary aim of the study is to compare the effect of three different interventions on lifestyle risk factors and biological risk factors for type 2 diabetes in depressed Cambodians. The three different interventions are lifestyle, lifestyle plus medication therapy management, and social services.
Primary Outcome
Change from baseline in depressive symptoms according to the Hopkins Symptom Checklist
Interventions
- BEHAVIORAL Lifestyle
- BEHAVIORAL Social Services
- BEHAVIORAL Lifestyle Plus Medication Therapy Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-09 |
| Phase | NA |
What the finished NCT02502929 record still lists
NCT02502929 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Lifestyle is the first listed.
NCT02502929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02502929 about?
NCT02502929 is a clinical study titled "Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians". The primary aim of the study is to compare the effect of three different interventions on lifestyle risk factors and biological risk factors for type 2 diabetes in depressed Cambodians. The three different interventions are lifestyle, lifestyle plus medication therapy management, and social services...
What is the current status of trial NCT02502929?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2015-11. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02502929?
The interventions under investigation include: Lifestyle (BEHAVIORAL), Social Services (BEHAVIORAL), Lifestyle Plus Medication Therapy Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT02502929?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02502929's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia